Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Dermira
Marketing
Eli Lilly, Incyte's Olumiant notches atopic dermatitis trial win
Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?
Kyle Blankenship
Jan 27, 2020 10:30am
Lilly inks $1.1B Dermira deal as biopharma M&A gets underway
Jan 10, 2020 11:42am
Condé Nast's new digital buying plan scores with pharma
Dec 16, 2019 7:53am
Can Dupixent steal half of a $21B eczema market? Not so fast
Dec 11, 2019 10:42am
Amgen, GSK advance to #FierceMadness Elite 8
Mar 27, 2019 10:55am
Dermira taps real patients in first ads for Qbrexza
Mar 25, 2019 10:11am